Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | THAR |
---|---|---|
09:32 ET | 5359 | 2.6 |
09:33 ET | 330 | 2.62 |
09:35 ET | 6981 | 2.5801 |
09:37 ET | 1988 | 2.6243 |
09:39 ET | 2682 | 2.58 |
09:42 ET | 1840 | 2.5816 |
09:44 ET | 1270 | 2.5408 |
09:46 ET | 245 | 2.54 |
09:48 ET | 100 | 2.5996 |
09:50 ET | 2010 | 2.5402 |
09:51 ET | 3390 | 2.54 |
09:55 ET | 2728 | 2.4866 |
09:57 ET | 2569 | 2.5 |
10:00 ET | 190 | 2.4637 |
10:02 ET | 4100 | 2.47 |
10:04 ET | 506 | 2.48 |
10:06 ET | 1349 | 2.5 |
10:08 ET | 100 | 2.5 |
10:09 ET | 1119 | 2.4628 |
10:11 ET | 100 | 2.46 |
10:13 ET | 200 | 2.4501 |
10:15 ET | 200 | 2.4649 |
10:20 ET | 720 | 2.4983 |
10:22 ET | 2050 | 2.4701 |
10:26 ET | 1907 | 2.53 |
10:29 ET | 600 | 2.549 |
10:33 ET | 280 | 2.54 |
10:36 ET | 200 | 2.54 |
10:38 ET | 1263 | 2.53 |
10:40 ET | 9603 | 2.59 |
10:45 ET | 150 | 2.5 |
10:47 ET | 2044 | 2.55 |
10:51 ET | 2300 | 2.7199 |
10:56 ET | 800 | 2.77 |
11:00 ET | 445 | 2.76 |
11:02 ET | 561 | 2.76 |
11:03 ET | 2546 | 2.66 |
11:05 ET | 1450 | 2.71 |
11:07 ET | 620 | 2.6842 |
11:09 ET | 350 | 2.665 |
11:12 ET | 1018 | 2.707 |
11:18 ET | 250 | 2.7296 |
11:20 ET | 100 | 2.7 |
11:21 ET | 300 | 2.665 |
11:23 ET | 302 | 2.631 |
11:25 ET | 130 | 2.7 |
11:27 ET | 800 | 2.74 |
11:32 ET | 409 | 2.77 |
11:36 ET | 200 | 2.6676 |
11:38 ET | 1193 | 2.74 |
11:39 ET | 300 | 2.746046 |
11:41 ET | 500 | 2.75 |
11:43 ET | 523 | 2.73 |
11:45 ET | 7744 | 2.74 |
11:48 ET | 300 | 2.75 |
11:54 ET | 500 | 2.775 |
11:56 ET | 200 | 2.765899 |
12:01 ET | 1318 | 2.75 |
12:06 ET | 300 | 2.763 |
12:08 ET | 250 | 2.75 |
12:21 ET | 755 | 2.76 |
12:24 ET | 1445 | 2.8 |
12:26 ET | 424 | 2.78 |
12:28 ET | 1000 | 2.8 |
12:30 ET | 210 | 2.77 |
12:32 ET | 2724 | 2.7001 |
12:42 ET | 700 | 2.7579 |
12:48 ET | 100 | 2.75 |
12:50 ET | 8107 | 2.82 |
12:51 ET | 1400 | 2.84 |
12:53 ET | 544 | 2.83 |
12:55 ET | 2444 | 2.86 |
01:00 ET | 4072 | 2.8946 |
01:02 ET | 5308 | 2.88 |
01:04 ET | 3441 | 2.86 |
01:13 ET | 100 | 2.78 |
01:15 ET | 200 | 2.7801 |
01:22 ET | 302 | 2.7888 |
01:33 ET | 1266 | 2.8191 |
01:38 ET | 2113 | 2.785 |
01:40 ET | 100 | 2.7248 |
01:42 ET | 100 | 2.78 |
01:51 ET | 1051 | 2.79 |
01:56 ET | 249 | 2.7899 |
01:58 ET | 100 | 2.79 |
02:02 ET | 4265 | 2.7602 |
02:03 ET | 1141 | 2.8474 |
02:05 ET | 100 | 2.8118 |
02:07 ET | 288 | 2.81 |
02:27 ET | 200 | 2.78 |
02:30 ET | 100 | 2.78 |
02:36 ET | 2000 | 2.78 |
02:39 ET | 808 | 2.85 |
02:50 ET | 1200 | 2.78 |
02:54 ET | 2214 | 2.745 |
02:56 ET | 1160 | 2.72 |
02:59 ET | 2083 | 2.81 |
03:08 ET | 319 | 2.84 |
03:14 ET | 153 | 2.85 |
03:17 ET | 1501 | 2.804857 |
03:21 ET | 409 | 2.9 |
03:24 ET | 115 | 2.9 |
03:26 ET | 101 | 2.9 |
03:30 ET | 100 | 2.89 |
03:32 ET | 1926 | 2.95 |
03:33 ET | 3012 | 2.9 |
03:37 ET | 617 | 2.9 |
03:39 ET | 100 | 2.89 |
03:42 ET | 150 | 2.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tharimmune Inc | 3.1M | -0.1x | --- |
Actavia Life Sciences Inc | 3.1M | -7.5x | --- |
Revelation Biosciences Inc | 3.1M | 0.0x | --- |
TNF Pharmaceuticals Inc | 3.2M | -0.2x | --- |
Scinai Immunotherapeutics Ltd | 3.0M | -0.4x | --- |
Avenue Therapeutics Inc | 3.2M | -0.7x | --- |
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-55.46 |
Book Value | $11.67 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.